Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Brokerages

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have earned an average rating of “Buy” from the eleven analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $22.6667.

A number of research analysts recently issued reports on TRVI shares. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, May 6th. Wall Street Zen raised shares of Trevi Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Monday, April 20th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, May 20th. Finally, D. Boral Capital restated a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a research report on Friday, April 17th.

Institutional Investors Weigh In On Trevi Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TRVI. Pivotal bioVenture Partners Investment Advisor LLC grew its position in shares of Trevi Therapeutics by 9.7% during the third quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 1,256,782 shares of the company’s stock worth $11,500,000 after purchasing an additional 110,672 shares in the last quarter. Nan Fung Trinity HK Ltd. lifted its holdings in Trevi Therapeutics by 924.2% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 917,450 shares of the company’s stock worth $11,486,000 after purchasing an additional 827,875 shares in the last quarter. F m Investments LLC purchased a new position in Trevi Therapeutics in the 4th quarter worth approximately $3,023,000. Pictet Asset Management Holding SA boosted its stake in Trevi Therapeutics by 13,507.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,532,013 shares of the company’s stock worth $19,181,000 after purchasing an additional 1,520,754 shares during the period. Finally, Comerica Bank boosted its stake in Trevi Therapeutics by 19,481.8% in the 4th quarter. Comerica Bank now owns 83,027 shares of the company’s stock worth $1,039,000 after purchasing an additional 82,603 shares during the period. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Stock Performance

Shares of Trevi Therapeutics stock opened at $17.93 on Monday. The stock has a market cap of $2.55 billion, a P/E ratio of -56.03 and a beta of 1.00. The stock’s fifty day moving average is $15.06 and its 200 day moving average is $12.95. Trevi Therapeutics has a one year low of $5.71 and a one year high of $19.26.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Analysts predict that Trevi Therapeutics will post -0.47 EPS for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.